Slimane Allali1, Sylvie Fraitag2, Benjamin Terrier3, Christine Bodemer4, Martin Chalumeau5. 1. Department of General Pediatrics, Hôpital Necker-Enfants Malades, APHP, Paris Descartes University, 149 rue de Sèvres, 75015, Paris, France. slimane.allali@nck.aphp.fr. 2. Department of Pathology, Hôpital Necker-Enfants Malades, APHP, Paris Descartes University, 149 rue de Sèvres, 75015, Paris, France. sylvie.fraitag@nck.aphp.fr. 3. Department of Internal Medicine, Hôpital Cochin, APHP, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. benjamin.terrier@cch.aphp.fr. 4. Department of Dermatology, Hôpital Necker-Enfants Malades, APHP, Paris Descartes University, 149 rue de Sèvres, 75015, Paris, France. christine.bodemer@nck.aphp.fr. 5. Department of General Pediatrics, Hôpital Necker-Enfants Malades, APHP, Paris Descartes University, 149 rue de Sèvres, 75015, Paris, France. martin.chalumeau@nck.aphp.fr.
Abstract
UNLABELLED: Colchicine is not usually considered a treatment option for cutaneous lesions of Henoch-Schönlein purpura (HSP) in children. We report a case of pediatric HSP with severe chronic and relapsing cutaneous manifestations that were resistant to corticosteroids. Colchicine had remarkable therapeutic efficacy, with positive dechallenge and rechallenge, without any adverse effects. CONCLUSION: Colchicine should be considered for chronic, severe cutaneous lesions of pediatric HSP. WHAT IS KNOWN: Colchicine is not usually considered a treatment option for cutaneous lesions of Henoch-Schönlein purpura (HSP) in children. What is New: We report a case of pediatric HSP with severe cutaneous manifestations that responded well to colchicine. Colchicine should be considered for chronic cutaneous lesions of HSP in children.
UNLABELLED: Colchicine is not usually considered a treatment option for cutaneous lesions of Henoch-Schönlein purpura (HSP) in children. We report a case of pediatric HSP with severe chronic and relapsing cutaneous manifestations that were resistant to corticosteroids. Colchicine had remarkable therapeutic efficacy, with positive dechallenge and rechallenge, without any adverse effects. CONCLUSION:Colchicine should be considered for chronic, severe cutaneous lesions of pediatric HSP. WHAT IS KNOWN: Colchicine is not usually considered a treatment option for cutaneous lesions of Henoch-Schönlein purpura (HSP) in children. What is New: We report a case of pediatric HSP with severe cutaneous manifestations that responded well to colchicine. Colchicine should be considered for chronic cutaneous lesions of HSP in children.
Entities:
Keywords:
Chronic severe cutaneous lesions; Colchicine; Henoch-Schönlein purpura; Immunoglobulin A vasculitis; Leukocytoclastic vasculitis
Authors: Jan Dudley; Graham Smith; Anne Llewelyn-Edwards; Kate Bayliss; Katie Pike; Jane Tizard Journal: Arch Dis Child Date: 2013-07-11 Impact factor: 3.791
Authors: Vera Ramelli; Sebastiano A G Lava; Giacomo D Simonetti; Mario G Bianchetti; Gian Paolo Ramelli; Gregorio P Milani Journal: Eur J Pediatr Date: 2017-02-04 Impact factor: 3.183
Authors: Lampros Fotis; Paul V Tuttle; Kevin W Baszis; Peri H Pepmueller; Terry L Moore; Andrew J White Journal: Pediatr Rheumatol Online J Date: 2016-06-23 Impact factor: 3.054